Torcetrapib

Cat. No.: 0225LY-1239

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Torcetrapib is a CETP inhibitor designed to modulate cholesterol transfer between HDL and LDL, though it failed in clinical trials due to safety concerns.

Synonym: CP-529414; 262352-17-0; Torcetrapib; CP 529414; CP-529,414; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; 1(2H)-Quinolinecarboxylic acid, 4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)-; ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate; Ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate

CAS No.: 262352-17-0

Compound CID: 159325

Formula: C₂₆H₂₅F₉N₂O₄

Formula Weight: 600.47

Specification

Targets&IC50: CETP: 37 nM

Relative Density: 1.42 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Torcetrapib can be used in biochemical studies to investigate the impact of CETP inhibition on cholesterol transport and vascular health.